The purpose of this study is to find out what effects (good and bad) immunotherapy treatment
using the p53 vaccine (Ad.p53-DC) in combination with Nivolumab and Ipilimumab has on small
cell lung cancer. Immunotherapy is a cancer therapy that uses the body's immune system to
fight cancer cells.
This study can be divided into three different phases: initial Induction Immunotherapy,
Maintenance Immunotherapy and Retreatment.
During the Induction Immunotherapy phase (4 x 21 day cycles) of the study, participants will
receive Ipilimumab and Nivolumab on Day 1 of each cycle for 4 cycles. Participants will
receive the p53 vaccine on Days 1 and 15 of cycle 1 and then again on Day 8 of Cycle 2.
Beginning on Day 1 of Cycle 5 participants will start Maintenance Immunotherapy. During this
phase of the study, participants will receive Nivolumab only on Day 1 of every 4 week period.
Participants will also receive the p53 vaccine three additional times (every 4 weeks over a
12 week period). During Maintenance Immunotherapy you will continue to receive Nivolumab only
on Day 1 of each additional 4 week period that you take part until your disease progresses.
The Retreatment phase of the study may be available to participants whose doctor feels they
would benefit from retreatment and if they qualify for this retreatment. During retreatment,
participants would receive the combination of Ipilimumab and Nivolumab or Nivolumab alone
every three weeks for a maximum of one additional year.
P53 Vaccine production
The p53 vaccine will be made by inserting the p53 gene (a gene is a hereditary unit of all
living organism within a cell) into a subset of the participant's own white blood cells. The
insertion of the gene into their white blood cells will occur in the laboratory, after their
cells have been extracted from their body through a procedure called leukopheresis (similar
- Histologic or cytologic diagnosis of SCLC
- Recurrence to at least one prior treatment with a platinum containing regimen
(cisplatin or carboplatin) including limited stage (LS) and extensive stage (ES)
initial presentations. Note: In patients with SCLC the most frequent platinum
containing doublet used is etoposide-carboplatin. However, etoposide-cisplatin and
irinotecan or topotecan combined with either carboplatin or cisplatin are platinum
doublet regimens that can sometimes be used and thus would be allowed for the purposes
of trial enrollment and eligibility.
- Excluded are patients who upon relapse may be still considered for a salvage
concurrent chemo-radiation approach.
- Willing and able to provide written informed consent/assent for the trial.
- Be 18 years of age or older on day of signing informed consent
- Have measurable disease based on Response Evaluation in Solid Tumors (RECIST) 1.1
- Have a performance status of 0 - 1 on the Eastern Cooperative Oncology Group (ECOG)
- Demonstrate adequate organ function. All screening labs should be performed within 30
days of treatment initiation.
- Life expectancy of >4 months.
- Favorable tumor p53 biomarker profile defined by ≥ 50% p53 positive tumor cells by
immunohistochemistry. Tumor p53 biomarker evaluations may be performed with either
original or recurrent tumor although samples from recurrent disease are preferred.
- Females of childbearing potential should have a negative urine or serum pregnancy
within 72 hours prior to receiving the first dose of study medication. If the urine
test is positive or cannot be confirmed as negative, a serum pregnancy test will be
- Females of childbearing potential should be willing to use 2 methods of birth control
or be surgically sterile, or abstain from heterosexual activity for the course of the
study through 120 days after the last dose of study medication.
- Males should agree to use an adequate method of contraception starting with the first
dose of study therapy through 120 days after the last dose of study therapy.
- Currently participating and receiving study therapy or has participated in a study of
an investigational agent and received study therapy or used an investigational device
within 4 weeks of the first dose of treatment.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid or any other form
of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
Therapy: Systemic steroid doses of less than 10 mg of prednisone daily or its
equivalent are allowed in patients receiving physiologic replacement steroid doses for
both criteria 2 and 8.
- Has a known history of active Bacillus Tuberculosis (TB)
- Hypersensitivity to Ipilimumab and/or nivolumab or any of its excipients.
- Has had a prior anti-cancer monoclonal antibody (mAb) excluding any anti-PD-1 and/or
anti-PD-L1 checkpoint inhibitor within 4 weeks prior to study Day 1 or who has not
recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents
administered more than 4 weeks earlier.
- Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at
baseline) from adverse events due to a previously administered agent. - Note:
Potential participants with ≤ Grade 2 neuropathy are an exception to this criterion
and may qualify for the study. - Note: If potential participant received major
surgery, they must have recovered adequately from the toxicity and/or complications
from the intervention prior to starting therapy.
- Has a known additional malignancy that is progressing or requires active treatment.
Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
skin that has undergone potentially curative therapy or in situ cervical cancer. Other
malignancies that remain without evidence of disease or recurrence, 2 years or more
after curative therapy are also considered part of this exception.
- Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis. Patients with previously treated brain metastases may participate provided
they are stable (without evidence of progression by imaging for at least 2 weeks prior
to the first dose of trial treatment and any neurologic symptoms have returned to
baseline), have no evidence of new or enlarging brain metastases, and are not using
steroids for at least 7 days prior to trial treatment. This exception does not include
carcinomatous meningitis which is excluded regardless of clinical stability.
- Any diagnosis of autoimmune disease (confirmed by medical records or appropriate
- Known history of, or any evidence of active, non-infectious pneumonitis.
- Has an active infection requiring systemic therapy
- History or current evidence of any condition, therapy, or laboratory abnormality that
might confound the results of the trial, interfere with participation for the full
duration of the trial, or is not in the best interest of the person to participate, in
the opinion of the treating investigator.
- Known psychiatric or substance abuse disorders that would interfere with cooperation
with the requirements of the trial.
- Pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the pre-screening or screening visit
through 120 days after the last dose of trial treatment.
- Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
- Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
[qualitative] is detected)
- Has received a live vaccine within 30 days of planned start of study therapy. Note:
Seasonal influenza vaccines for injection are generally inactivated flu vaccines and
are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live
attenuated vaccines, and are not allowed.
- Excluded are patients who upon relapse may be still considered for a salvage
concurrent chemo-radiation approach